Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs KE Holdings Inc (BEKE) Price & Performance

Amgen, Inc.Trade
KE Holdings IncTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs KE Holdings Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while KE Holdings Inc trades at $17.28 (market cap $18.92B). The key difference: Amgen, Inc. is far larger — about 11.8× KE Holdings Inc's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.

AMGNBEKE
Market Cap
$224.14B$18.92B
Sector
HealthTechnology
52-Week High
$417.20$20.36
52-Week Low
$271.18$14.26
Enterprise Value
$267.45B$14.66B
Dividend Yield
2.43%1.63%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About KE Holdings Inc

KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.

Read more on BEKE